含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶,它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来,关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JM...含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶,它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来,关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JMJD6不仅能通过其酶活性影响肿瘤细胞的表观遗传状态,还能通过与其他分子如核受体、转录因子等互作,调节肿瘤相关基因的表达。研究表明,JMJD6与多种肿瘤类型如乳腺癌、肺癌和前列腺癌等的发生密切相关。此外,JMJD6的活性与肿瘤患者的预后及药物敏感性相关,使其成为潜在的治疗靶点。目前,针对JMJD6的临床研究正在探索其作为生物标志物及治疗靶点的潜力,例如在抗肿瘤药物开发中的应用。本文旨在综述JMJD6的调控机制和临床研究进展,为未来的研究方向及临床应用提供理论基础。Jumonji C-domain containing protein 6 (JMJD6) is a Fe(II) and α-ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lysine residues in precursor mRNA fragments. In recent years, the role of JMJD6 in tumorigenesis, development, and metastasis has been gradually elucidated. JMJD6 not only influences the epigenetic state of tumor cells through its enzymatic activity, but also regulates the expression of tumor-related genes by interacting with other molecules, such as nuclear receptors and transcription factors. Studies have shown that JMJD6 is closely associated with the occurrence of various types of tumors, such as breast cancer, lung cancer, and prostate cancer. Furthermore, the activity of JMJD6 is related to the prognosis and drug sensitivity of cancer patients, making it a potential therapeutic target. Currently, clinical studies on JMJD6 are exploring its potential as a biomarker and therapeutic target, for example, in the application of the development of anti-tumor drugs. This paper aims to review the regulatory mechanisms and clinical research progress of JMJD6, providing a theoretical basis for future research directions and clinical applications.展开更多
文摘含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶,它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来,关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JMJD6不仅能通过其酶活性影响肿瘤细胞的表观遗传状态,还能通过与其他分子如核受体、转录因子等互作,调节肿瘤相关基因的表达。研究表明,JMJD6与多种肿瘤类型如乳腺癌、肺癌和前列腺癌等的发生密切相关。此外,JMJD6的活性与肿瘤患者的预后及药物敏感性相关,使其成为潜在的治疗靶点。目前,针对JMJD6的临床研究正在探索其作为生物标志物及治疗靶点的潜力,例如在抗肿瘤药物开发中的应用。本文旨在综述JMJD6的调控机制和临床研究进展,为未来的研究方向及临床应用提供理论基础。Jumonji C-domain containing protein 6 (JMJD6) is a Fe(II) and α-ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lysine residues in precursor mRNA fragments. In recent years, the role of JMJD6 in tumorigenesis, development, and metastasis has been gradually elucidated. JMJD6 not only influences the epigenetic state of tumor cells through its enzymatic activity, but also regulates the expression of tumor-related genes by interacting with other molecules, such as nuclear receptors and transcription factors. Studies have shown that JMJD6 is closely associated with the occurrence of various types of tumors, such as breast cancer, lung cancer, and prostate cancer. Furthermore, the activity of JMJD6 is related to the prognosis and drug sensitivity of cancer patients, making it a potential therapeutic target. Currently, clinical studies on JMJD6 are exploring its potential as a biomarker and therapeutic target, for example, in the application of the development of anti-tumor drugs. This paper aims to review the regulatory mechanisms and clinical research progress of JMJD6, providing a theoretical basis for future research directions and clinical applications.
